| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22014 |
| Drug | Nirmatrelvir/Ritonavir |
| Brand | Paxlovid® |
| Indication | Is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. |
| Assessment Process | |
| Rapid review commissioned | 08/03/2022 |
| Rapid review completed | 15/03/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Nirmatrelvir/Ritonavir (Paxlovid®) not be considered for reimbursement at the submitted price*. |
| Full pharmacoeconomic assessment commissioned by HSE | 05/05/2023 |
| Pre-submission consultation with Applicant | 08/09/2023 |
| Full submission received from Applicant | 01/02/2024 |
| Preliminary review sent to Applicant | 14/02/2024 |
| NCPE assessment re-commenced | 13/03/2024 |
| Factual accuracy sent to Applicant | 30/05/2024 |
| NCPE assessment re-commenced | 07/06/2024 |
| NCPE assessment completed | 20/06/2024 |
| NCPE assessment outcome | The NCPE recommends that Paxlovid be considered for reimbursement if cost-effectiveness can be improved* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
